Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price

Gibofsky, 2014, Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: a synopsis, Am J Manag Care, 20, S128 Kvien, 2004, Epidemiology and burden of illness of rheumatoid arthritis, PharmacoEconomics, 22, 1, 10.2165/00019053-200422001-00002 Carmona, 2002, The prevalence of rheumatoid arthritis in the general population of Spain, Rheumatol Oxf Engl, 41, 88, 10.1093/rheumatology/41.1.88 Gissel, 2016, Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany, Z Rheumatol, 75, 1006, 10.1007/s00393-016-0071-9 Singh, 2016, 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis, Arthritis Rheumatol Hoboken NJ, 68, 1, 10.1002/art.39480 Sanmartí, 2015, 2014 update of the consensus statement of the Spanish society of rheumatology on the use of biological therapies in rheumatoid arthritis, Reumatol Clín Engl Ed, 11, 279, 10.1016/j.reuma.2015.05.001 Smolen, 2017, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update, Ann Rheum Dis, 76, 960, 10.1136/annrheumdis-2016-210715 Smolen, 2016, Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force, Ann Rheum Dis, 75, 3, 10.1136/annrheumdis-2015-207524 Smolen, 2014, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Ann Rheum Dis, 73, 492, 10.1136/annrheumdis-2013-204573 Kuek, 2007, Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution, Postgrad Med J, 83, 251, 10.1136/pgmj.2006.052688 Tanaka, 2013, Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal?, Ann Rheum Dis, 72, 10.1136/annrheumdis-2012-202350 Microsoft Word – Informe técnico ANTI-TNF – reumatologia.pdf (Internet). Available from: http://sescam.castillalamancha.es/sites/sescam.castillalamancha.es/files/documentos/farmacia/reumatologia.pdf [cited 21.06.17]. L GQ, Coral-Alvarado P. Economic Impact of Rheumatic Diseases. Chall Rheumatol (Internet). 2011. Available from: http://www.intechopen.com/books/challenges-in-rheumatology/economic-impact-of-rheumatic-diseases [cited 5.03.18]. Plasencia, 2013, The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients, Arthritis Res Ther, 15, R79, 10.1186/ar4258 González, 2015, Anti-tnf dose and anti-drug antibody levels in rheumatic and psoriasis patients: Economic repercussion, Eur J Clin Pharm Aten Farm, 17, 4 González-Fernández, 2018, Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price, Int J Clin Phar, 40, 1528, 10.1007/s11096-018-0703-z Balsa, 2007, ¿Cómo se evalúa una respuesta inadecuada en un paciente con artritis reumatoide en la práctica clínica?, Reumatol Clín, 3, 38, 10.1016/S1699-258X(07)73597-0 Real Decreto Legislativo 3/2011, de 14 de noviembre, por el que se aprueba el texto refundido de la Ley de Contratos del Sector Público. BOE-A-2011-17887 (Internet). Available from: https://www.boe.es/buscar/act.php?id=BOE-A-2011-17887 [cited 3.03.17]. Real Decreto-ley 4/2010, de 26 de marzo, de racionalización del gasto farmacéutico con cargo al Sistema Nacional de Salud. Jefatura del Estado Referencia: BOE-A-2010-5030 (Internet). Available from: https://www.boe.es/buscar/doc.php?id=BOE-A-2010-5030 [cited 2.07.17]. Gómez-De Rueda, 2017, Análisis y evaluación del coste del tratamiento anti-TNFalfa en artritis reumatoide y espondilitis, J Negat No Posit Results, 233 Estudio del coste de las terapias biológicas en patologías reumáticas según práctica clínica de un hospital (Internet). Revista de la OFIL. 2017. Available from: http://www.revistadelaofil.org/estudio-del-coste-las-terapias-biologicas-patologias-reumaticas-segun-practica-clinica-hospital/ [cited 8.07.17]. Ramírez-Herráiz, 2013, Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice, Clin Exp Rheumatol, 31, 559 Ivorra, 2016, Análisis de costes de la utilización de fármacos biológicos para la artritis reumatoide en primera línea de tratamiento tras respuesta inadecuada a metotrexato en función del peso de los pacientes, Reumatol Clín, 12, 123, 10.1016/j.reuma.2015.07.008 REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients – ScienceDirect (Internet). Available from: https://www.sciencedirect.com/science/article/pii/S2405844017310150 [cited 25.07.18]. Pascual-Salcedo, 2011, Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis, Rheumatol Oxf Engl, 5, 52 Westhovens, 2016, Costs of drugs for treatment of rheumatic diseases, RMD Open, 2, e000259, 10.1136/rmdopen-2016-000259 Guideline on similar biological medicinal products. 2014. (Internet). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Real Decreto 177/2014, de 21 de marzo, por el que se regula el sistema de precios de referencia y de agrupaciones homogéneas de medicamentos en el Sistema Nacional de Salud, y determinados sistemas de información en materia de financiación y precios de los medicamentos y productos sanitarios (Internet). Noticias Jurídicas. Available from: http://noticias.juridicas.com/base_datos/Fiscal/526168-rd-177-2014-de-21-mar-sistema-de-precios-de-referencia-y-de-agrupaciones.html [cited 22.07.18]. Rencz, 2015, Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe, World J Gastroenterol WJG, 21, 37, 10.3748/wjg.v21.i6.1728 Farfan-Portet, 2014, Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?, Eur J Health Econ HEPAC Health Econ Prev Care, 15, 223, 10.1007/s10198-013-0538-4 Paintaud, 2017, Rationale for therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases, Ther Drug Monit, 39, 339, 10.1097/FTD.0000000000000410